Malignant Peripheral Nervous System Neoplasm

Malignant Peripheral Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

60 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20
Recruiting: 13
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–14 of 14 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02180867	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery	completed	Phase 2 / Phase 3	140	National Cancer Institute (NCI)NIH	3	Jun 17, 2026	clinicaltrials
NCT03433183	SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors	completed	Phase 2	21	Sarcoma Alliance for Research through CollaborationOTHER